Bristol Myers Squibb - International Biopharmaceutical Industry

Home
Current
Features
Editorial
Archives
Archived
Issues
Events
Sponsored
Report
Company
Profile
A-D

E-M

N-S

T-Z

Menu
Application
Notes
News
eBooks

Aldevron
Podcast
Generic selectors

Exact matches only

Search in title

Search in content

Post Type Selectors

Current Edition

news

Two cancer cell therapy studies succeeded. Why did a third fail?

In two major clinical trials, researchers found cell therapy dramatically outperformed the standard of care used for the past few decades to counter a common type of ...

15 December 2021 news Breyanzi | Bristol Myers Squibb

Continue Reading →

news

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials haven't been com...

30 September 2021 news AstraZeneca | Bristol Myers Squibb

Continue Reading →

news

Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite...

10 September 2021 news Adaptimmune | Bluebird Bio

Continue Reading →

news

GSK, in race to catch up with rivals, wins expanded approval for cancer drug

GSK has high hopes for Jemperli as it transitions to what's being called the "new GSK," with a greater focus on experimental drugs for infectious disease, cancer and ...

20 August 2021 news Bristol Myers Squibb | cancer

Continue Reading →

news

Regeneron drug extends survival in lung cancer trial, lifting company’s hopes in field

Since its first approval in first-line lung cancer in 2016, Keytruda has proved a tough competitor for rival drugmakers to challenge with their own therapies. Bristol...

13 August 2021 news Bristol Myers Squibb | drugmakers

Continue Reading →

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Current Edition

Upcoming Events

Advertisement

Two cancer cell therapy studies succeeded. Why did a third fail?

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

GSK, in race to catch up with rivals, wins expanded approval for cancer drug

Regeneron drug extends survival in lung cancer trial, lifting company’s hopes in field

International Biopharmaceutical Industry